JP4234207B2 - アレルギー性気管支肺アスペルギルス症の診断方法 - Google Patents
アレルギー性気管支肺アスペルギルス症の診断方法 Download PDFInfo
- Publication number
- JP4234207B2 JP4234207B2 JP52870398A JP52870398A JP4234207B2 JP 4234207 B2 JP4234207 B2 JP 4234207B2 JP 52870398 A JP52870398 A JP 52870398A JP 52870398 A JP52870398 A JP 52870398A JP 4234207 B2 JP4234207 B2 JP 4234207B2
- Authority
- JP
- Japan
- Prior art keywords
- rasp
- abpa
- fumigatus
- patients
- ige
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 title claims abstract description 103
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000003745 diagnosis Methods 0.000 title abstract description 22
- 239000013566 allergen Substances 0.000 claims abstract description 92
- 241000282414 Homo sapiens Species 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 description 105
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 description 105
- 241001225321 Aspergillus fumigatus Species 0.000 description 78
- 229960004784 allergens Drugs 0.000 description 43
- 210000002966 serum Anatomy 0.000 description 41
- 208000006673 asthma Diseases 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 201000003883 Cystic fibrosis Diseases 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 206010070834 Sensitisation Diseases 0.000 description 13
- 208000010668 atopic eczema Diseases 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 13
- 230000008313 sensitization Effects 0.000 description 13
- 230000000172 allergic effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000000405 serological effect Effects 0.000 description 11
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 10
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 10
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 201000009961 allergic asthma Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000010181 skin prick test Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 201000009267 bronchiectasis Diseases 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000000802 Galectin 3 Human genes 0.000 description 3
- 108010001517 Galectin 3 Proteins 0.000 description 3
- 101000868115 Homo sapiens Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000037446 allergic sensitization Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 230000010485 coping Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000054 fungal extract Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000009215 host defense mechanism Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 101150040383 pel2 gene Proteins 0.000 description 2
- 101150050446 pelB gene Proteins 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- -1 corticoid steroid Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604815A SE9604815D0 (sv) | 1996-12-20 | 1996-12-20 | A metod of diagnosis |
| SE9604815-2 | 1996-12-20 | ||
| PCT/SE1997/002172 WO1998028624A1 (en) | 1996-12-20 | 1997-12-19 | Methods for diagnosis of allergic bronchopulmonary aspergillosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001507130A JP2001507130A (ja) | 2001-05-29 |
| JP2001507130A5 JP2001507130A5 (OSRAM) | 2005-03-10 |
| JP4234207B2 true JP4234207B2 (ja) | 2009-03-04 |
Family
ID=20405166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52870398A Expired - Lifetime JP4234207B2 (ja) | 1996-12-20 | 1997-12-19 | アレルギー性気管支肺アスペルギルス症の診断方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6830891B1 (OSRAM) |
| EP (1) | EP0946873B1 (OSRAM) |
| JP (1) | JP4234207B2 (OSRAM) |
| AT (1) | ATE252238T1 (OSRAM) |
| AU (1) | AU5505198A (OSRAM) |
| DE (1) | DE69725606T2 (OSRAM) |
| DK (1) | DK0946873T3 (OSRAM) |
| ES (1) | ES2210591T3 (OSRAM) |
| PT (1) | PT946873E (OSRAM) |
| SE (1) | SE9604815D0 (OSRAM) |
| WO (1) | WO1998028624A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040099061A1 (en) | 1997-12-22 | 2004-05-27 | Mks Instruments | Pressure sensor for detecting small pressure differences and low pressures |
| EP1135162B1 (en) * | 1998-11-30 | 2008-10-29 | Cytos Biotechnology AG | Ordered molecular presentation of allergens, method of preparation and use |
| DE69934233T2 (de) * | 1999-12-02 | 2007-10-25 | Council Of Scientific & Industrial Research | Aspergillus Fumigatus Peptidsequenzen zur Diagnose von Aspergillose |
| JP2004527450A (ja) * | 2000-04-06 | 2004-09-09 | シーア ファーマスーティカルズ エルエルシー | 微生物送達システム |
| US7175983B2 (en) * | 2001-11-02 | 2007-02-13 | Abmaxis, Inc. | Adapter-directed display systems |
| US7201057B2 (en) | 2004-09-30 | 2007-04-10 | Mks Instruments, Inc. | High-temperature reduced size manometer |
| US7141447B2 (en) | 2004-10-07 | 2006-11-28 | Mks Instruments, Inc. | Method of forming a seal between a housing and a diaphragm of a capacitance sensor |
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| EP1739428A1 (en) * | 2005-07-01 | 2007-01-03 | Institut Pasteur | In vitro diagnostic method and kit for an aspergillus infection |
| IES20090466A2 (en) * | 2008-06-13 | 2010-03-03 | Nat Univ Ireland | P2/P2A/P2B gene sequences as diagnostic targets for the identification of fungal and yeast species |
| US10585098B2 (en) | 2009-11-23 | 2020-03-10 | The Johns Hopkins University | Optimizing diagnostics for galactofuranose containing antigens |
| US10288611B2 (en) | 2009-11-23 | 2019-05-14 | The Johns Hopkins University | Lateral flow device for diagnosing microbial infections |
| WO2015095195A1 (en) | 2013-12-16 | 2015-06-25 | The Johns Hopkins University | Interferon-gamma release assays for diagnosis of invasive fungal infections |
| CN105859848A (zh) * | 2016-05-30 | 2016-08-17 | 复旦大学 | 烟曲霉Asp f 4的线性抗原表位最小基序肽Asp f 4219-226及其扩展短肽 |
| CN108646025A (zh) * | 2018-05-03 | 2018-10-12 | 辽宁汇普源生物医学科技开发有限责任公司 | 基于IgG3抗体捕获气传过敏原的ELISA试剂盒 |
| CN108845137A (zh) * | 2018-05-03 | 2018-11-20 | 沈阳汇敏源生物科技有限责任公司 | 基于IgG1抗体捕获食物过敏原的ELISA试剂盒 |
| CN108845124A (zh) * | 2018-05-03 | 2018-11-20 | 辽宁汇普源生物医学科技开发有限责任公司 | 基于IgG1抗体检测气传过敏原的ELISA试剂盒 |
| CN108872566A (zh) * | 2018-07-19 | 2018-11-23 | 锦州医科大学 | 基于IgG2抗体检测气传过敏原的ELISA试剂盒 |
| CN108872567A (zh) * | 2018-07-19 | 2018-11-23 | 锦州医科大学 | 基于IgD抗体检测气传过敏原的ELISA试剂盒 |
| CN109283336A (zh) * | 2018-09-21 | 2019-01-29 | 锦州医科大学附属第医院 | 基于IgD抗体捕获气传过敏原的ELISA试剂盒 |
| WO2025153527A1 (en) * | 2024-01-19 | 2025-07-24 | Englmeier Ludwig | Diagnostic use of immunoglobulin e |
| EP4588490A1 (en) * | 2024-01-19 | 2025-07-23 | Englmeier, Ludwig | Diagnostic use of immunoglobulin e |
-
1996
- 1996-12-20 SE SE9604815A patent/SE9604815D0/xx unknown
-
1997
- 1997-12-19 DE DE69725606T patent/DE69725606T2/de not_active Expired - Lifetime
- 1997-12-19 US US09/319,806 patent/US6830891B1/en not_active Expired - Lifetime
- 1997-12-19 ES ES97951399T patent/ES2210591T3/es not_active Expired - Lifetime
- 1997-12-19 JP JP52870398A patent/JP4234207B2/ja not_active Expired - Lifetime
- 1997-12-19 EP EP97951399A patent/EP0946873B1/en not_active Expired - Lifetime
- 1997-12-19 DK DK97951399T patent/DK0946873T3/da active
- 1997-12-19 WO PCT/SE1997/002172 patent/WO1998028624A1/en not_active Ceased
- 1997-12-19 PT PT97951399T patent/PT946873E/pt unknown
- 1997-12-19 AU AU55051/98A patent/AU5505198A/en not_active Abandoned
- 1997-12-19 AT AT97951399T patent/ATE252238T1/de active
-
2003
- 2003-07-02 US US10/612,358 patent/US20050074410A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SE9604815D0 (sv) | 1996-12-20 |
| US20050074410A1 (en) | 2005-04-07 |
| WO1998028624A1 (en) | 1998-07-02 |
| EP0946873A1 (en) | 1999-10-06 |
| DE69725606T2 (de) | 2004-08-05 |
| DE69725606D1 (de) | 2003-11-20 |
| EP0946873B1 (en) | 2003-10-15 |
| PT946873E (pt) | 2004-02-27 |
| JP2001507130A (ja) | 2001-05-29 |
| ATE252238T1 (de) | 2003-11-15 |
| US6830891B1 (en) | 2004-12-14 |
| AU5505198A (en) | 1998-07-17 |
| ES2210591T3 (es) | 2004-07-01 |
| DK0946873T3 (da) | 2004-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4234207B2 (ja) | アレルギー性気管支肺アスペルギルス症の診断方法 | |
| Kurup et al. | Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA | |
| RU2235131C2 (ru) | Моноклональное антитело, нуклеиновая кислота и вектор, кодирующие антитело, и использование антитела для диагностики и лечения злокачественных заболеваний | |
| TWI283749B (en) | Antibody pair screening methods | |
| KR102228185B1 (ko) | 땅콩 알레르기 진단을 위한 개선된 분석방법 | |
| CN113287013A (zh) | 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法 | |
| JP5252339B2 (ja) | Ｐａｄ４及び抗ｐａｄ４抗体の測定方法並びに関節リウマチの検出方法 | |
| US8263356B2 (en) | Antibodies and methods for predicting dental caries | |
| CN104364374B (zh) | 癌的检测方法及识别胰脏特异性的核糖核酸酶1的抗体 | |
| KR102031845B1 (ko) | 신규한 면역글로불린 e의 에피토프, 그와 결합하는 항체 및 상기 항체를 포함하는 시료 중 면역글로불린 e를 분석하기 위한 키트 | |
| US20090176245A1 (en) | Rheumatoid Arthritis Test Method and Treating Method | |
| Devendra et al. | The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes: D. Devendra et al: Distinguishing insulin autoantibody from insulin antibody | |
| JP2000239300A (ja) | アポリポ蛋白質ａ−ｉに対するモノクローナル抗体 | |
| JP2019508684A (ja) | 活動性結核の診断のための方法及びキット | |
| CN111458522A (zh) | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 | |
| JP4597132B2 (ja) | クローン病抗体エピトープペプチド及びクローン病の検査試薬 | |
| KR102132964B1 (ko) | 쯔쯔가무시균 유래 엑소좀을 이용한 쯔쯔가무시병의 진단방법 | |
| Sarma et al. | Immunodiagnosis of ABPA | |
| Casey et al. | Peptides specific for Mycobacterium avium subspecies paratuberculosis infection: diagnostic potential | |
| Robles et al. | Isolation of the Taenia crassiceps antigens from a phage display cDNA library and evaluation of their use for diagnosis of neurocysticercosis | |
| KR20200049387A (ko) | 브루셀라균의 omp28에 특이적으로 결합하는 단일클론항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 | |
| CN110229221B (zh) | 一种用于检测侵袭性白色念珠菌病的抗原及其用途 | |
| CN120842380A (zh) | 一种针对猫Fel d4的单克隆抗体及其应用 | |
| HK40033205B (en) | Antibody capable of resisting panspermia specific plasmodium lactate dehydrogenase | |
| CN120757639A (zh) | 一种p-Tau217单分子检测试剂盒及其检测抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050726 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070319 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070514 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080707 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080828 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081202 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081211 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111219 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121219 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131219 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |